ECEric Xueyu Chen

Eric Xueyu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Xueyu Chen has a total of 602 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integrated Whole-Genome and Transcriptome Sequencing Reveals Divergent Evolutionary Processes Across Biliary Tract Cancer Subtypes

    by Felix E.G. Beaudry, Duhan Yendi, Danielle L.A. Arshinoff, Nicholas Light, Simona Perrotti, Erin Winter, Liam R. Cristant, Jingxiong Xu, Julie M. Wilson, Anna J. Dodd, et al.

    Biliary tract cancer (BTC) comprises a family of rare malignancies subclassified by anatomy and pathology. However, this classification scheme may obscure shared biology and limit patient stratification. Here, we tested whether BTC heterogeneity can be explained by coherent latent axes and evaluated the potential to unify diverse clinical and genomic factors under a tractable biological framework. Whole-genome and transcriptome sequencing was performed on 180 tumors enriched for tumor cells by laser capture microdissection to identify shared programs in BTC. Network integration across transcriptomic classes identified two consensus cancer subtypes (CCS). The CCS segregated with anatomical location of primary tumor, and gene expression marker analyses suggested that subtypes reflect tumor cell of origin differences. The CCS displayed strikingly divergent molecular landscapes, explaining more variance than anatomical location of the primary tumor. CCS-B tumors were mutationally loaded with clock-like and APOBEC signatures and extrachromosomal DNA, whereas CCS-A tumors were characterized by chromosome-arm deletions. This approach showed that harnessing the genomic and transcriptomic diversity of BTC provides insights into shared biology and improves stratification.

  • Open Access

    Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study

    by Paul E. Oberstein, J. Randolph Hecht, Kanwal Raghav, Filippo Pietrantonio, Dirk Arnold, Victor Moreno, Eric Van Cutsem, Rozita Abdul Malik, Yong Sang Hong, Myung Ah Lee, et al.

    PURPOSE: Amivantamab, an EGFR-MET bispecific antibody with immune cell–directing activity, is approved in non–small cell lung cancer (NSCLC). Effective treatments are limited for chemorefractory metastatic colorectal cancer (mCRC). METHODS: OrigAMI-1 (ClinicalTrials.gov identifier: NCT05379595 ) is a phase Ib/II study evaluating amivantamab monotherapy in chemorefractory (2-3 prior lines) mCRC. Participants had centrally confirmed RAS / BRAF / EGFR ectodomain wild-type status, without ERBB2 / HER2 amplification. Participants with left-sided mCRC without (cohort A) or with (cohort B) prior anti-EGFR antibody treatment, or right-sided mCRC (cohort C) regardless of prior anti-EGFR treatment, received intravenous amivantamab 1,050 mg (1,400 mg for ≥80 kg) once every 2 weeks. The primary end point was objective response rate (ORR) per RECIST v1.1. RESULTS: By October 31, 2024, 94 participants received amivantamab monotherapy (median follow-up, 11.9 months). The median age was 60 years, and 65% of participants were male, with a median of 2 prior lines (94%, prior bevacizumab). In left-sided cohorts, the ORR was 29% (5 of 17) in cohort A and 19% (10 of 54) in cohort B; the median duration of response (DoR) was 9.0 months and 6.1 months, and the median progression-free survival (PFS) was 5.7 months and 4.6 months, respectively. In the right-sided cohort, the ORR was 22% (10 of 23; 43% had prior anti-EGFR), the median DoR was 9.8 months, and the median PFS was 3.7 months. Most frequent treatment-related grade ≥3 adverse events (AEs) were rash (7%), dermatitis acneiform (4%), and hypoalbuminemia (4%). One participant discontinued amivantamab because of a treatment-related AE. CONCLUSION: Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.


  • Open Access

    A Consensus Approach to the Incorporation of Total Neoadjuvant Therapy in a Treatment Algorithm for Stage I–III Resectable Rectal Cancer

    by Sami A. Chadi, Karineh Kazazian, Paul Savage, Christine Brezden-Masley, Ron Burkes, Eric Chen, Anand Govindarajan, Ali Hosni, Raymond Jang, Erin Kennedy, et al.

    Advances in surgical techniques, radiographic imaging capabilities, radiotherapy, and chemotherapy have led to improved outcomes for patients with rectal adenocarcinoma. Treatment strategies have correspondingly evolved, as seen with total neoadjuvant therapy (TNT) and organ preservation approaches. TNT is a treatment strategy for primary, non-metastatic, resectable mismatch repair proficient rectal cancer where the intent is to administer all appropriate adjuvant therapy in the preoperative phase, including both systemic therapy and chemoradiotherapy/radiotherapy. In this setting, TNT is increasingly administered for the purposes of maximizing tumour response to facilitate resection, improving treatment compliance, thus increasing the likelihood of a complete response to allow for organ preservation and for the possibility of improving survival. While several recent randomized controlled trials have described the role of TNT in the contemporary treatment of rectal cancer, there is significant heterogeneity in sequencing of treatments, dosing, allowance for non-operative management, and the potential for over-treatment. Our objective here was to incorporate current evidence to develop a consensus-based institutional treatment algorithm to be used in the ambulatory and multidisciplinary team setting for the treatment of stage I–III rectal cancer.

  • Top Cited Papers
    Open Access

    Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

    by Dung T Le, Gunnar Folprecht, Anna M Varghese, Martin Gutierrez, Marcus Noel, Nikolaos A Trikalinos, Eric Chen, Farshid Dayyani, S Lindsey Davis, Wen Wee Ma, et al.

    Background: Cysteine–cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b/2, open-label study evaluated BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy±nivolumab in advanced PDAC or metastatic CRC. Methods: Part 1 included patients with metastatic untreated (first-line (1L)) PDAC, 1L CRC, or previously treated (second or third line (2/3L)) microsatellite stable (MSS) CRC. Patients received 2 weeks of BMS-813160 monotherapy (300 mg two times a day, 600 mg once daily, 300 mg once daily, or 150 mg once daily) and then BMS-813160+chemotherapy (gemcitabine+nab-paclitaxel (gem/nabP; 1L PDAC), 5-fluorouracil+leucovorin+irinotecan (FOLFIRI; 1L CRC)), or nivolumab (2/3L MSS CRC). Part 2 included patients with metastatic 1L PDAC or 2L CRC. Patients received BMS-813160 300 mg two times a day+gem/nabP±nivolumab (1L PDAC), BMS-813160 300 mg two times a day or 150 mg once daily+FOLFIRI (2L CRC), or chemotherapy alone. Primary endpoints were safety and pharmacodynamics (Part 1) and efficacy (Part 2). Results: In Part 1, 22 of 75 (29%) and 54 of 72 (72%) patients experienced a treatment-related adverse event during monotherapy lead-in and overall, respectively. Two dose-limiting toxicities (rash and pericardial effusion with pericarditis, both grade 3) occurred. In Part 2, patients with 1L PDAC who received BMS-813160 300 mg two times a day+gem/nabP+nivolumab achieved an overall response rate (ORR) of 37% (13/35); the median duration of response (DOR) was 45 weeks (95% CI 26.1 to not evaluable). ORRs with BMS-813160 300 mg two times a day+gem/nabP and gem/nabP alone were 26% (9/35) and 28% (9/32), respectively; median DORs were 121 and 31 weeks, respectively. Progression-free survival rates at 24 weeks were 56% (BMS-813160 300 mg two times a day+gem/nabP+nivolumab), 56% (BMS-813160 300 mg two times a day+gem/nabP), and 50% (gem/nabP). ORRs in 2L CRC were 19% (6/32; BMS-813160 300 mg two times a day+FOLFIRI), 13% (4/32; BMS-813160 150 mg once daily+FOLFIRI), and 27% (7/26; FOLFIRI). Conclusions: In 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated. Trial registration number: NCT03184870 .


  • Open Access

    Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis

    by Yacob Saleh, Zeynep Baskurt, Abdul Rehman Farooq, Rachel Goodwin, Jennifer Knox, Grainne O’KAne, Eric Xueyu Chen

    Background: Systemic therapy containing immune checkpoint inhibitors (ICIs) has become the standard of care for patients with advanced hepatocellular carcinoma (HCC). A prior analysis from the pre-ICI era demonstrated a moderate correlation between progression-free survival (PFS) and overall survival (OS). We performed a literature-based meta-analysis to include randomized phase III trials (RCTs) of ICIs to evaluate surrogate endpoints for OS in advanced HCC. Methods: RCTs evaluating systemic therapies in advanced HCC published/presented between 2007 and 2024 were identified through a systemic literature search. Hazard ratios (HRs) for OS and PFS were extracted. The change in the overall response rates (ΔORR) was calculated as the difference between experimental and control arms. Pearson correlation and mixed-effects meta-regression analyses were performed. Strength of correlation was determined using the criteria from the Institute for Quality and Efficiency in Health Care (IQWIG). Surrogate threshold effect (STE) was determined for each comparison when possible. Subgroup analysis was performed. A p < 0.05 was considered to be statistically significant. Results: In total, 21 1st-line and 12 2nd-line RCTs were included. Of 1st-line RCTs, 48% evaluated ICIs either alone or in combination. There was a weak correlation between HR-PFS and HR-OS (n = 18, r = 0.64, 95% confidence interval (CI): 0.25–0.85, p = 0.004) and no correlation between ΔORR and HR-OS (n = 21, r = 0.42, 95% CI: −0.01 – 0.72, p = 0.06). The STE for HR-PFS was 0.68. Subgroup analyses revealed a moderate correlation between HR-PFS and HR-OS in 1st-line RCTs enrolling fewer patients with nonviral etiology (n = 9, r = 0.75, 95% CI: 0.17–0.94, p = 0.02). There was, however, a strong correlation between HR-PFS and HR-OS in 2nd-line RCTs (n = 10, r = 0.90, 95% CI: 0.61–0.98, p < 0.001). The STE for HR-PFS in 2nd-line RCTs was 0.87. Conclusion: The correlation between HR-PFS and HR-OS is weak in 1st-line RCTs in advanced HCC where OS remains the most appropriate endpoint. There is a strong association between HR-PFS and HR-OS for 2nd-line RCTs, suggesting that PFS is a suitable surrogate endpoint in that setting.


  • Open Access

    Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

    by Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, et al.

    Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above each Kaplan Meier curve.

  • Open Access

    Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

    by Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, et al.

    All CHIP variants identified in the study

  • Open Access

    Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

    by Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, et al.

  • Open Access

    Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

    by Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, et al.

    VAF of all CHIP variants split by cohort

  • Open Access

    Data from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors

    by Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, Robert J. Vanner, David F. Schaeffer, Aly Karsan, Howard Lim, Cheryl Ho, Sharlene Gill, Stephen Yip, et al.

    Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with treatment outcomes and adverse events. We reviewed cfDNA results from a local prospective solid tumor cohort (PREDiCT-l) and two randomized trials: Canadian Cancer Trials Group CO.26 [durvalumab + tremelimumab (D + T) or best supportive care in metastatic colorectal cancer] and Canadian Cancer Trials Group PA.7 (gemcitabine and nab-paclitaxel ± D + T in metastatic pancreatic adenocarcinoma). CHIP+ was defined as any mutation in DNMT3A, TET2, or ASXL1 with a variant allele frequency ≥2%. Presumed germline variants (variant allele frequency >40%) were removed. The first line of treatment after cfDNA was reviewed for grade ≥3 and dose-limiting toxicities. The prevalence of CHIP in the 465 included patients was 10% to 30%, and it was more common as age increased (P = 0.003). DNMT3A was the gene most frequently mutated in all cohorts. Patients with CHIP in PA.7 treated with immunotherapy showed an improved progression-free survival versus CHIP− [HR = 0.55 (0.28–1.07); P = 0.079, P-interaction = 0.098 (multivariable)]. However, patients with CHIP treated with chemotherapy in PREDiCT-l showed a trend toward worse progression-free survival [HR = 1.82 (0.98–3.38); P = 0.059]. There was no difference in adverse event rates between CHIP ± groups for those treated with chemotherapy or immunotherapy. CHIP is common in patients with solid tumors. Although not appearing to affect rates of adverse events, CHIP may affect outcomes from immunotherapy or chemotherapy.Significance:Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on growing evidence of common CHIP variants in patients with solid tumors. The results suggest a possible clinical impact of CHIP on treatment outcomes from immunotherapy or chemotherapy. This may have implications for treatment selection for patients with solid tumors.